Member Info for BuenaVista

Oh dear. I have never said "we’ll never get the chance to buy at these prices again". And I'm not in any "gang".

So that looks like manufactured guff that's not even half an hour old.

Derek, you really do play the idiot.

For example: "And 6 years of being in this share has taught me that the communications have always hyped positive stuff and glossed over potential negative stuff." You have not been invested for 6 years. You can say whatever you like about the previous management but the fact is that the company is now under completely new management, so whatever you say about the previous management is now completely irrelevant. You can't even do FUD well.

"But heh you are just nasty people" and "it’s down to me to balance the debate" make you sound like Trump with your drivel about balancing facts with your manufactured guff.

You are your own worst enemy Derek but I guess that's your role in life. You're a scouse aren't you? You like to wind people up with insults and fabrications and then play the poor innocent wronged victim when they trash you. Pathetic.

@Derek,

Firstly, congratulations on getting into Avacta back in 2019. You must have banked a massive packet when you sold out at the height of the Covid frenzy. Something like a 12 bagger?

Secondly, CC stated during the business presentation at the time of the AGM that "...the initial data in SGC will be released in late 2025 and the data in TNBC will be released in the first half of 2026." Nothing has changed.

Thirdly, are you really trying to make out that CC delivering on her timelines is somehow a negative?

Fourthly, you are such a warrior hero, we should all club toegther to get a statue of you made that we can put under a tree, where pigeons perch.

And finally, twat.

...I was just getting used to that.

Up 25% over the week.

Data will be presented at ESMO: "A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors"

Late report of an 8am (08:01?) trade and reversal

60 gone

60 reached

Anyone guided by BritishBulls for their trading will be. Since 48.85...

Do you think this was the 'big' RNS?

Dare I say some HWNIs will be selling now knowing they can get the shares back at 50p.

...and/or

o An equity fundraise

That last one has to in there as a backstop or top-up.

15 January is clearly the latest the moneymen are prepared to let Avacta's current funds stretch into Q1/2026.

All good I think - confidence abounding. I wonder how the share price will react today.

They're martyrs, at 10p a post. Once you understand that everything is clear.

Dr_DMS, a moron, wrote: "They have 26 patents and doesn't look like any are for the Precision delivery method. CC said there would be a new patent coming out but still waiting...."

Everyone, look at https://avacta.com/wp-content/uploads/2025/07/Avacta_Corp_23July2025.pdf slide 30. Dr_DMS, ask your carer to show you.

TA-meisters have been predicting a move up to around 85p (max). That's just from playing around with crayons.

I think CC said the patent was filed in September last year, in which case it likely won't be published until March next year (18 months).

https://assets.publishing.service.gov.uk/media/62b014a4e90e0765d348809c/Patents-Timeline.pdf

Same goes if it is a GB patent that is abandoned and filed instead as a EP or WO patent covering the UK amongst others, as is likely, than it will still be March next year.

'Scaffold proteins' patents have been filed by Avacta since 2017.

This is the World patent from the patent family: https://patents.google.com/patent/WO2019008335A1/en

"Summary of the Invention

"The inventors studied the Stefin A scaffold protein with aims of improving its properties such as its thermal stability. Building on their insights into the protein structure and function, they designed a range of changes and substitutions to improve those properties. This led to various surprising results including unpredicted anomalies where for example it might have been expected for the protein to behave in a certain manner, but for which the objective findings were at odds with predictions (for example the Q.42D/E anomaly discussed in detail below). The result of this substantial research and intellectual effort is a comprehensive teaching of how to alter the thermal stability of the Stefin A protein and how those changes in thermal stability deliver benefits to its use as a scaffold protein.

"Thus the invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to19,21to25,27 to28,35 to37,39,41,43 to44,46to47,49 to50,52 to53,55 to58,63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1;"

- - - - -

This suggests that the invention is relevant to the application of Affimers, e.g. for AffyXell, Gen 3 PDCs, other Tx applications, and diagnostics.

Substantially similar to, if not exactly the same, as this AU patent application:

https://patentimages.storage.googleapis.com/da/ad/63/24d73e41f4a41e/AU2025202133A1.pdf

Breeched!

Let's say the hands are fumbling for the kecks but they're not on yet